A Comparative Pharmacokinetic Study of Single-Dose Administration of HR091506 Tablets From Different Batches in Healthy Subjects

NCT07076459 | Completed Phase 1

• 1 other identifier: HR091506-104
• Study Type: interventional
• Target: 36
• Locations: 1 country
• Sites: 1

Brief Summary

To evaluate the pharmacokinetic characteristics of HR091506 tablets in different batches in healthy subjects after single administration.

Conditions

Health Volunteer

Outcome Measures

Primary Outcomes (4)

• Cmax: Maximum plasma concentration. Blood samples will be collected.

  From 0 hour predose up to 36 hours postdose

• AUC0-t: Area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration. Blood samples will be collected.

  From 0 hour predose up to 36 hours postdose

• AUC0-∞: Area under the plasma concentration-time curve from time 0 to infinity. Blood samples will be collected.

  From 0 hour predose up to 36 hours postdose

• Tmax: Observed time to reach Cmax. Blood samples will be collected.

  From 0 hour predose up to 36 hours postdose

Secondary Outcomes (1)

• Incidence of treatment emergent AEs (TEAEs)

  From Signing of Informed Consent Form (ICF) up to Safety Follow Up (Up to Day 24)

Study Arms (6)

Sequence 1

EXPERIMENTAL

Period 1: HR091506 tablet T1 Period 2: HR091506 tablet T2 Period 3: HR091506 tablet R

Drug: HR091506 tablet

Sequence 2

EXPERIMENTAL

Period 1: HR091506 tablet T2 Period 2: HR091506 tablet R Period 3: HR091506 tablet T1

Drug: HR091506 tablet

Sequence 3

EXPERIMENTAL

Period 1: HR091506 tablet R Period 2: HR091506 tablet T1 Period 3: HR091506 tablet T2

Drug: HR091506 tablet

Sequence 4

EXPERIMENTAL

Period 1: HR091506 tablet T2 Period 2: HR091506 tablet T1 Period 3: HR091506 tablet R

Drug: HR091506 tablet

Sequence 5

EXPERIMENTAL

Period 1: HR091506 tablet T1 Period 2: HR091506 tablet R Period 3: HR091506 tablet T2

Drug: HR091506 tablet

Sequence 6

EXPERIMENTAL

Period 1: HR091506 tablet R Period 2: HR091506 tablet T2 Period 3: HR091506 tablet T1

Drug: HR091506 tablet

Interventions

HR091506 tablet DRUG

In each period under fed conditions, subjects received oral administration of either HR091506 tablet（T1）, HR091506 tablet（T2）, or HR091506 tablet（R）.

Sequence 1; Sequence 2; Sequence 3; Sequence 4; Sequence 5; Sequence 6

Eligibility Criteria

• Age: 18 Years - 50 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy male or female between the ages of 18 and 50 years, inclusive.
• At least 50.0 kg for male subjects, 45.0 kg for female subjects, with a Body Mass Index (BMI) between 19.0-26.0 kg/m2, inclusive (BMI = weight/height2).
• Prior to screening, during the trial, and for 90 days after the last administration, subjects (including male subjects) must not have plans to conceive and must voluntarily adopt effective contraceptive measures.
• Subjects who could understand the nature, significance, potential benefits, inconvenience, and potential risks of the study, understand the procedures and methods, be willing to complete the trial strictly following the protocol, and voluntarily sign the informed consent.

You may not qualify if:

• Subjects with history of drug or food allergies.
• Subjects with a history of diseases related to the circulatory, endocrine, nervous, digestive, respiratory, hematolymphatic, immune, mental, skin, bone, muscle, urogenital, mucosal, and metabolic systems.
• Use of any medication within 14 days prior to dosing.
• Subjects who have taken any clinical investigational products or participated in the clinical research of medical devices within 90 days before the trial, or plan to participate in other clinical trials during the study.
• Subjects who have donated blood or experienced blood loss greater than 300 mL, or have received a blood transfusion or used blood products within 90 days prior to screening.
• Subjects who take more than 5 cigarettes per day on average within 90 days prior to the study or do not agree to prohibit smoking during the study.

Sponsors & Collaborators

• Jiangsu HengRui Medicine Co., Ltd.: lead

Study Sites (1)

Cangzhou Central Hospital

Cangzhou, Hebei, 061000, China

Location

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 15, 2025
• First Posted: July 22, 2025
• Study Start: July 10, 2025
• Primary Completion: August 18, 2025
• Study Completion: August 18, 2025
• Last Updated: August 28, 2025

Record last verified: 2025-07

Locations

CN (1)